oncology companies

Companies whose enriched business profile is tagged “oncology”, drawn from their SEC filings + website text. Sorted by market capitalization; every figure is delayed data from SEC EDGAR + market data, shown with its as-of date.

• Lilly (Eli) (LLY) Health Care — Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies. ask →
• AbbVie (ABBV) Health Care — A diversified global biopharmaceutical leader with a strong footprint in immunology, neuroscience, and aesthetics, supported by a pipeline expanding into obesity. ask →
• NOVARTIS AG (NVS) Health Care — Novartis is a leading global pharmaceutical company focused on discovering and developing innovative, high-efficacy medicines across oncology, immunology, and neuroscience. ask →
• Amgen (AMGN) Health Care — Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease. ask →
• Pfizer (PFE) Health Care — A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas. ask →
• Moderna (MRNA) Health Care — Moderna is a pioneer in mRNA technology, working to transform medicine by developing a broad pipeline of prophylactic vaccines and therapeutic medicines. ask →
• Incyte (INCY) Health Care — Incyte is a biopharmaceutical company focused on discovering and developing innovative medicines for oncology and inflammatory conditions. ask →
• Exelixis (EXEL) Health Care — Exelixis is a commercial-stage oncology biotechnology company with a strong focus on developing small-molecule treatments for various types of cancer. ask →
• Summit Therapeutics (SMMT) Health Care — A biopharmaceutical company dedicated to the clinical advancement of its lead bispecific antibody, ivonescimab, for oncology applications. ask →
• Corcept Therapeutics (CORT) Health Care — Corcept Therapeutics is a commercial-stage biotechnology company pioneering cortisol modulation therapies to treat severe endocrine, oncologic, and metabolic conditions. ask →
• IMMUNITYBIO INC (IBRX) Health Care — ImmunityBio develops innovative immunotherapies and cell-based cancer vaccines that leverage its Cancer BioShield platform to treat oncology and infectious disease patients. ask →
• IOVANCE BIOTHERAPEUTICS INC (IOVA) Health Care — Iovance is a pioneer in tumor infiltrating lymphocyte (TIL) cell therapy, offering the first one-time, individualized T cell treatment for advanced solid tumor cancers. ask →
• CG ONCOLOGY INC (CGON) Health Care — CG Oncology is an immuno-oncology company developing bladder-sparing therapeutics for patients with non-muscle invasive bladder cancer. ask →
• ERASCA INC (ERAS) Health Care — Erasca is a precision oncology company dedicated to shutting down the RAS/MAPK pathway to effectively treat patients with cancer. ask →
• RELAY THERAPEUTICS INC (RLAY) Health Care — Relay Therapeutics is a precision medicine company leveraging a protein-motion discovery platform to develop targeted therapies for oncology and genetic diseases. ask →
• CELCUITY INC (CELC) Health Care — Celcuity is a biotechnology company developing gedatolisib, a targeted PI3K/mTOR inhibitor, to treat various cancer indications. ask →
• ARCUS BIOSCIENCES INC (RCUS) Health Care — A clinical-stage biopharmaceutical company focused on discovering and developing innovative, small-molecule and antibody-based oncology therapies through a robust pipeline and strategic collaborations. ask →
• ENLIVEN THERAPEUTICS INC (ELVN) Health Care — Enliven Therapeutics is a precision oncology company developing next-generation small molecule inhibitors, led by its clinical-stage BCR-ABL program for chronic myeloid leukemia. ask →
• NURIX THERAPEUTICS INC (NRIX) Health Care — Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate bexobrutideg in CLL and partnerships spanning Roche, Gilead, and Sanofi. ask →
• CELLDEX THERAPEUTICS INC (CLDX) Health Care — Celldex Therapeutics is a clinical-stage biotechnology firm developing novel monoclonal antibodies and antibody-drug conjugates to treat complex inflammatory and oncology diseases. ask →
• SELLAS LIFE SCIENCES GROUP INC (SLS) Health Care — SELLAS Life Sciences is a clinical-stage biotech developing novel immunotherapies to address hematologic and solid tumor cancers. ask →
• IMMUNOME INC (IMNM) Health Care — Immunome is a clinical-stage biotechnology company leveraging a proprietary platform to discover and develop novel, targeted oncology therapeutics. ask →
• XENCOR INC (XNCR) Health Care — A clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines using its proprietary protein engineering platforms to treat cancer and autoimmune diseases. ask →
• BIOHAVEN LTD (BHVN) Health Care — Biohaven is a biopharmaceutical firm developing a diverse pipeline of innovative therapies for complex diseases in neuroscience, immunology, obesity, and oncology. ask →
• ZYMEWORKS INC (ZYME) Health Care — A clinical-stage biotechnology firm building value through a portfolio of novel multifunctional biotherapeutics and strategic royalty assets. ask →
• NOVOCURE LTD (NVCR) Health Care — Novocure is an oncology company utilizing proprietary Tumor Treating Fields (TTFields) to disrupt cancer cell division through wearable, non-invasive electric field therapy. ask →
• ORIC PHARMACEUTICALS INC (ORIC) Health Care — ORIC Pharmaceuticals is a clinical-stage biotech company developing precision therapies designed to overcome therapeutic resistance in cancer. ask →
• TYRA BIOSCIENCES INC (TYRA) Health Care — Tyra Biosciences is a clinical-stage biotech company using its proprietary SNAP platform to develop targeted small molecule inhibitors for FGFR-driven cancers and other diseases. ask →
• CULLINAN THERAPEUTICS INC (CGEM) Health Care — Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of targeted therapies for cancer and autoimmune diseases. ask →
• AKTIS ONCOLOGY INC (AKTS) Health Care — Aktis Oncology is developing a pipeline of precision radiopharmaceuticals designed to deliver potent cancer-killing radiation directly to tumors. ask →
• KURA ONCOLOGY INC (KURA) Health Care — A clinical-stage oncology biopharmaceutical company developing targeted, small-molecule precision therapies for cancer patients. ask →
• Odyssey Therapeutics, Inc. (ODTX) Health Care — A clinical-stage biotechnology company developing novel small molecule therapeutics for oncology and inflammatory conditions. ask →
• CORVUS PHARMACEUTICALS INC (CRVS) Health Care — A clinical-stage biotechnology company developing ITK-inhibitor therapies to treat T-cell lymphomas and immune-mediated inflammatory diseases. ask →
• GYRE THERAPEUTICS INC (GYRE) Health Care — A biopharmaceutical company combining a commercial-stage fibrosis franchise in China with a U.S.-based R&D platform for targeted protein degraders and oncology therapies. ask →
• IMMIX BIOPHARMA INC (IMMX) Health Care — Immix Biopharma is a clinical-stage biopharmaceutical company developing novel therapeutic candidates to address critical unmet needs in oncology and inflammatory disease treatment. ask →
• NUVECTIS PHARMA INC (NVCT) Health Care — Nuvectis Pharma is a clinical-stage biotech developing targeted precision medicines, including SRC/YES1 kinase inhibitors and Factor B inhibitors, to address unmet needs in oncology and chronic inflammatory diseases. ask →
• PRIME MEDICINE INC (PRME) Health Care — Prime Medicine is pioneering a versatile and precise "search-and-replace" gene editing platform to create potentially curative, one-time therapies for severe genetic diseases. ask →
• MONOPAR THERAPEUTICS INC (MNPR) Health Care — Monopar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of oncology therapeutics, including novel radiopharmaceutical agents. ask →
• ARVINAS INC (ARVN) Health Care — Arvinas is a pioneer in the field of targeted protein degradation, leveraging its PROTAC platform to develop a new class of medicines for complex oncology and neurology diseases. ask →
• ANGIODYNAMICS INC (ANGO) Health Care — A medical technology company specializing in image-guided, minimally invasive devices for cardiovascular disease, vascular access, and oncology treatments. ask →
• EIKON THERAPEUTICS INC (EIKN) Health Care — Eikon Therapeutics is an oncology-focused biopharmaceutical company advancing a clinical pipeline of novel immune-oncology and DNA damage response candidates discovered through its proprietary research platform. ask →
• C4 THERAPEUTICS INC (CCCC) Health Care — C4 Therapeutics is a clinical-stage biotechnology company leveraging its TORPEDO platform to develop targeted protein degraders for the treatment of oncology and inflammatory diseases. ask →
• ABEONA THERAPEUTICS INC (ABEO) Health Care — Abeona Therapeutics is a commercial-stage biopharmaceutical firm providing the first autologous cell-based gene therapy for the treatment of rare, debilitating RDEB skin wounds. ask →
• BridgeBio Oncology Therapeutics, Inc. (BBOT) Health Care — A clinical-stage oncology firm developing next-generation small-molecule inhibitors to target RAS and PI3K-driven cancers through monotherapy and combination strategies. ask →
• CENTURY THERAPEUTICS INC (IPSC) Health Care — Century Therapeutics is pioneering scalable, off-the-shelf allogeneic cell therapies using an iPSC-derived platform to treat autoimmune diseases and cancer. ask →
• IMMUNEERING CORP CLASS A (IMRX) Health Care — Immuneering is a clinical-stage oncology company developing a new class of Deep Cyclic Inhibitors designed to overcome the limitations of chronic targeted therapies in cancer treatment. ask →
• MACROGENICS INC (MGNX) Health Care — A clinical-stage biotechnology company leveraging proprietary bispecific DART technology and antibody-drug conjugates to develop novel cancer immunotherapies. ask →
• ADC THERAPEUTICS SA (ADCT) Health Care — A commercial-stage oncology company pioneering antibody drug conjugates (ADCs) for patients with B-cell malignancies. ask →
• WHITEHAWK THERAPEUTICS INC (WHWK) Health Care — Clinical-stage oncology company developing a pipeline of next-generation antibody-drug conjugates targeting solid tumors. ask →
• ZENTALIS PHARMACEUTICALS INC (ZNTL) Health Care — Zentalis Pharmaceuticals is developing azenosertib, a potentially first-in-class, oral, small-molecule WEE1 inhibitor as a targeted treatment for ovarian and other solid tumors. ask →
• COMPASS THERAPEUTICS (CMPX) Health Care — Clinical-stage biopharma company developing next-generation bispecific and agonistic antibody therapies targeting angiogenesis and the tumor microenvironment to treat solid tumors. ask →
• Pyxis Oncology, Inc. (PYXS) Health Care — A clinical-stage oncology company developing a novel antibody-drug conjugate targeting the tumor microenvironment to treat difficult-to-treat solid tumors like HNSCC. ask →
• CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP) Health Care — Corbus Pharmaceuticals is a clinical-stage biotechnology company developing a Nectin-4-targeting antibody-drug conjugate for cancer and a novel CB1 inverse agonist for obesity. ask →
• ONKURE THERAPEUTICS INC CLASS A (OKUR) Health Care — OnKure Therapeutics is a clinical-stage biopharmaceutical company developing next-generation precision small molecule inhibitors to target PI3Kα-driven cancers and vascular anomalies. ask →
• ELICIO THERAPEUTICS INC (ELTX) Health Care — Elicio Therapeutics is developing lymph node-targeted, off-the-shelf immunotherapies for mKRAS-driven solid tumors using its proprietary AMP technology platform. ask →
• CONTEXT THERAPEUTICS INC (CNTX) Health Care — Context Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of T cell engaging bispecific antibodies to treat solid tumors. ask →
• KARYOPHARM THERAPEUTICS INC (KPTI) Health Care — Karyopharm Therapeutics develops novel cancer therapies using its proprietary XPO1 inhibition platform, with the lead drug XPOVIO currently used in multiple myeloma and a late-stage pipeline targeting myelofibrosis. ask →

Not quite it? Describe exactly what you want →

Data: SEC EDGAR (filings) + market data (fundamentals, delayed daily-close). Figures shown with their as-of date.

Last updated 2026-10-08.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.